Bio-Inspired-Microbiopsy-Device - BIMoDe
Bio-Inspired-Microbiopsy-Device - BIMoDe

Bio-Inspired-Microbiopsy-Device - BIMoDe

BIMoDe - Revolutionizing minimally invasive micro-biopsy with AI, biomimicry and advanced catheter technology

Periode
-
Looptijd
42 months
Deel van call / Programma
/
Projectpartners
ERASMUSMC
TU Delft
Synaptive Medical Ezgif.com Webp To Png Converter
Deam

The BIMoDe project is developing advanced micro-biopsy tools to enhance (cancer) diagnosis and treatment, targeting difficult-to-reach tissues with precision. Erasmus MC and TUDelft, through the Convergence-pact, aim to lead in health tech, partnering globally for instrument design and workflow enhancements. Collaborating with experts in low field MRI technology- Synaptive Medical Inc. and minimally invasive instrument development - DEAM B.V., we are innovating in the realm of safer, more effective biopsy procedures, with the aim to transform patient care and personalize  (cancer) therapy. We will share research and innovations via journals, conferences, and digital platforms, engaging stakeholders for swift technology implementation.

Annually, 18 million new cancer cases are diagnosed globally, with the Netherlands recording 120,000 in 2022, a steady 30-year rise. Nearly all patients require biopsies, often burdensome and costly, and prone to complications. Enhanced, less invasive biopsy tools could reduce complications, streamline healthcare, and improve patient outcomes and healthcare economics.

Plethora of medica treatments with cancer being a prominent exponent hinge on precise biopsy-based tissue analysis for diagnosis, therapy initiation, and prognosis. However, accessing hard-to-reach (cancerous) tissues poses challenges with conventional tools, affecting treatment plans and delaying personalized therapies. The BIMoDe project addresses this by developing minimally invasive micro-biopsy devices. These advanced tools, utilizing submillimeter catheter technology, aim to efficiently navigate and sample both primary affected tissues, and in the case of cancer spread metastatic cells in lymph nodes or other tissues, regardless of anatomical complexity. By analyzing and integrating various information sources, supported by tailored AI modalities, we aim to redesign biopsy techniques, enhance safety and accuracy, and improve patient outcomes in cancer treatment.

BIMoDe Consortium is aiming at the following goals:

  1. MRI-guided bio-inspired flexible ultrathin microbiopsy device suited for image guided maximal tissue sampling gain with minimal collateral damage
  2. BIMoDe digital module for workflow support & analysis is an AI-driven analytical module capable of advising on surgical workflow and instrumental design
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.